All patients (n=292) | Good responders† (n=103) | Moderate responders† (n=115) | Non-responders† (n=74) | |
---|---|---|---|---|
Demographics | ||||
Age, years | 52.8±12.7 | 50.5±11.7‡ | 54.4±12.7‡ | 53.7±13.8 |
Female, n (%) | 239 (82) | 79 (77) | 95 (83) | 65 (88) |
Body mass index | 26.0±5.6 | 25.9±5.4 | 25.7±5.2 | 26.7±6.5 |
Smoking, n (%) | 77 (27) | 32 (32) | 29 (26) | 16 (22) |
Glomerular filtration rate§ | 118.6±39.3 | 121.5±38.1 | 114.6±39.8 | 120.6±40.7 |
DMARD and previous biological therapy | ||||
Previous DMARD | 2.9±1.2 | 2.7±1.1*‡ | 3.0±1.4‡ | 3.0±1.3* |
Methotrexate use, n (%) | 223 (76) | 82 (80) | 87 (76) | 54 (73) |
Methotrexate dose, mg/week | 19.7±7.0 | 20.9±6.3 | 19.3±7.5 | 18.8±7.2 |
Prednisone use, n (%) | 83 (28) | 26 (25) | 35 (30) | 22 (30) |
Prednisone dose, mg/day | 8.2±3.9 | 7.3±4.1 | 8.5±3.9 | 8.6±3.7 |
Other DMARD than methotrexate, n (%) | 96 (33) | 41 (40) | 34 (30) | 21 (28) |
Previous biological agent, n (%)¶ | 89 (31) | 19 (18)*‡ | 41 (36)‡ | 29 (39)* |
Disease status | ||||
Disease duration, years | 8 (3–16) | 8 (2–4)‡ | 9 (3–8)‡ | 7 (3–7) |
Rheumatoid factor, n (%) | 207 (72) | 74 (73) | 84 (74) | 49 (66) |
Erosive disease, n (%) | 206 (72) | 70 (69) | 83 (74) | 53 (72) |
HAQ | 1.3±0.7 | 1.2±0.8 | 1.4±0.7 | 1.3±0.7 |
DAS28 | 5.2±1.3 | 5.0±1.2‡ | 5.7±1.2‡** | 4.7±1.5** |
Erythrocyte sedimentation rate, mm/h | 23 (12–0) | 17 (9–31)‡ | 29 (14–46)‡** | 20 (10–40)** |
C-reactive protein, mg/l | 8 (3–1) | 6 (3–20) | 11 (4–23)** | 6 (2–17)** |
Mean values±SD, median and IQR, or percentages are shown.
↵* There was a significant difference between EULAR good and non-responders for previous DMARD (p=0.047) and previous biological agent use (p=0.002).
↵† Last observation carried forward data were used for patients who discontinued the treatment with etanercept before 6 months.
↵‡ There was a significant difference between good and moderate EULAR responders for age (p=0.017); previous DMARD (p=0.0034); DAS28 (p<0.001); previous biological agent use (p=0.005); disease duration (p=0.038) and erythrocyte sedimentation rate (p<0.001).
↵§ Glomerular filtration rate according to the Cockcroft–Gault formula.
↵¶ Previous biological agents consisted of infliximab and adalimumab.
↵** There was a significant difference between moderate and EULAR non-responders for DAS28 (p<0.001); erythrocyte sedimentation rate (p=0.039); C-reactive protein (p=0.033).
DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; HAQ, health assessment questionnaire.